Neuphoria Therapeutics Inc.
NEUP
Positions held
Your positionsNEUP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $18.13M | Enterprise value | -$1.70M | Trailing P/E | — | Forward P/E | -1.36 |
| PEG | — | Price / book | 0.61 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -15.7% |
| Profit margin | 0.0% | ROE | -61.7% | ROA | -19.7% | Debt / equity | 0.00 |
| Current ratio | 27.85 | Free cash flow | -$8.34M | Analyst recommendation | none | Mean target | — |
| 52w high | $19.21 | 52w low | $3.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0.0M | $0.0M | $0.0M | $15.0M |
| Op margin | -15.7% | — | — | — | 79.8% |
| Net income | -$4.9M | -$0.5M | $1.9M | -$9.9M | $11.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$0.2M | -$0.8M | -$2.3M | -$5.7M | $12.0M |
- Operating margin compressed to -15.7%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | — | $0.0M | $0.0M | $0.2M |
| Op margin | -767.3% | — | — | — | -8095.1% |
| Net income | -$13.5M | — | -$15.5M | -$21.4M | -$15.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.0M | — | -$17.8M | -$21.6M | -$14.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
2026-07-27 · Scancell sees high demand in retail share offer, seals £15.7m from UK investors
2026-07-24 · SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
2026-07-23 · Sector Update: Healthcare Stocks Rise Late Afternoon
2026-07-23 · Sector Update: Healthcare Stocks Rise Thursday Afternoon
2026-07-23 · Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
2026-07-23 · Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Price (daily)
Full chart · RSI · MACD · patterns